Filings · News reference
Up to $400,000,000COMMON STOCKWe have entered into a Sales Agreement with Guggenheim Securities, LLC ("Guggenheim Securities"), dated May 6, 2022, as amended by that certain Amendment No. 1 to Sales Agreement,
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
Read original at benzingaGuggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.
Read original at benzingaFiled: 2026-08-10 AccNo: 0001193125-26-342695 Size: 155 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar